[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100506223":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":27,"locations":18,"responsibleParty":37,"collaborators":39,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":18,"enrollmentInfo":51,"targetDuration":18,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":66,"whyStopped":18,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":18},{"fullName":5,"class":6},"University Hospital Tuebingen","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Molecular genetic diagnostic","Next-Generation-Sequencing (NGS)-methods",[12],"Genetic: Molecular genetic diagnostic",[14],{"type":15,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"GENETIC","With the help of modern, highly sensitive analysis methods (NGS), such as ultra-low high-throughput sequencing, even the smallest amounts of circulating cell-free nucleic acids in the blood can be detected. In the individual course of therapy, the changes in concentration of the tumor-specific variants can thus be continuously monitored and appropriate therapy decisions can be made. The presence of minimal residual diseases and the development of resistance mutations can also be examined using this technique.",[9],null,[20,24],{"name":21,"affiliation":22,"role":23},"Christopher Schroeder, Dr.","University Hospital Tübingen","PRINCIPAL_INVESTIGATOR",{"name":25,"affiliation":22,"role":26},"Stephan Ossowski, Prof. Dr.","STUDY_CHAIR",[28,33],{"name":21,"role":29,"phone":30,"phoneExt":31,"email":32},"CONTACT","+49 7071 29","72296","christopher.schroeder@med.uni-tuebingen.de",{"name":34,"role":29,"phone":30,"phoneExt":35,"email":36},"Julian Broche, Dr.","61298","julian.broche@med.uni-tuebingen.de",{"type":38,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[40],{"name":41,"class":6},"German Consortium for Translational Cancer Research","100506223","circulating-cell-free-nucleic-acids-in-cancer-therapy-monitoring--01-100506223",false,"NCT05871593","CIRculating Cell-free nUcLeic Acids in Cancer Therapy Monitoring -01","CIRCULATING-01","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Advanced tumor disease\n* Ability to consent\n* Existence of a declaration of consent signed by the patient and physician (informed consent for study participation and Comprehensive Cancer Center (CCC) biobank\n* Existence or planned implementation of tumor-normal sequencing (usually carried out in a diagnostic context upon presentation at the Molecular Tumor Board (MTB)\n\nExclusion Criteria:\n\n\\- No therapy recommendation by MTB","ALL","18 Years",{"count":52,"type":53},200,"ESTIMATED","INTERVENTIONAL",[56],"NA","In cooperation with the molecular tumor board of the University Hospital Tübingen (UKT), a prospective collection of blood samples during the course of therapy is planned. It is a pilot study in which the technical feasibility of the approach (Highly Sensitive Next-Generation Sequencing (NGS) methods) initially should to be evaluated and further developed.",[59],"Next-Generation-Sequencing",[59,61,62,63,64,65],"Cell free DNA","Cell free RNA","Circulating tumor DNA","Circulating tumor RNA","Course of therapy","NOT_YET_RECRUITING","2023-05-12",{"date":69,"type":70},"2023-05-23","ACTUAL",{"date":72,"type":53},"2023-10",{"date":74,"type":53},"2026-10",{"name":5,"class":6}]